Call for expressions of interest: Systematic reviews on dose optimization of the first-line TB medicines

World Health Organization
July 22, 2020, 2:14 p.m.

22 July 2020, Geneva | The World Health Organization (WHO) Global Tuberculosis Programme has initiated a process for the collection and assessment of evidence on whether the dosing of rifampicin, isoniazid, ethambutol and pyrazinamide requires further optimization to safely improve treatment success and reduce unfavourable treatment outcomes in TB patients on first-line treatment regimens.

WHO's Global TB Programme is seeking support from independent consultants or group/s of experts with relevant expertise and experience to undertake systematic reviews to synthesise the evidence in the above-mentioned topic. The candidate/s should be able to work independently as well as interact regularly and collaboratively with the WHO Global TB Programme team and an external group of technical experts.

The expression of interest with a proposal can be submitted for systematic reviews covering all four first-line TB medicines (rifampicin, isoniazid, ethambutol and pyrazinamide) or selected medicines among them – depending on the interest of the experts. Please access the concept note and terms of reference for details of the work and requirements.

Please send your submission to the WHO Global TB Programme at gtbprogramme@who.int by 30 August 2020. The proposals received will go through a detailed review process and the selected consultants or group/s of experts will be notified on completion of the review process.


Source: WHO